https://www.selleckchem.com/products/Vandetanib.html 00, 1.09 (0.86-1.39), 1.48 (1.16-1.89); ptrend=0.002] but not with colorectal cancer (p=0.84), although an association [1.00, 0.98 (0.68-1.39), 1.24 (0.88-1.76); ptrend=0.08] was suggested for this cancer after excluding cases that occurred within 7 years of blood draw (pheterogeneity=0.06). CONCLUSIONS The VAT score predicted risks of postmenopausal breast cancer and can be used for risk assessment in diverse populations. IMPACT These findings provide specific evidence for a role of VAT in breast cancer. Copyright ©2020, American Association for Cancer Research.BACKGROUND The recent expansion of treatment options in acute myeloid leukemia (AML) has necessitated a greater understanding of patient preferences for treatment benefits about which little is known. METHODS We sought to quantify and assess heterogeneity of the preferences of AML patients for treatment outcomes. An AML-specific discrete choice experiment (DCE) was developed involving multiple stakeholders. Attributes included in the DCE were event-free survival (EFS), complete remission (CR), time in the hospital, short-term side effects, and long-term side effects. Continuously-coded conditional, stratified, and latent-class logistic regressions were used to model preferences of 294 AML patients. RESULTS Most patients were white (89.4%) and in remission (95.0%). A 10% improvement in the chance of CR was the most meaningful offered benefit (p less then 0.001). Patients were willing to trade up to 22 months of EFS or endure 8.7 months in the hospital or a two-step increase in long-term side effects to gain a 10% increase in chance of CR. Patients diagnosed at 60 years or older (21.6%) more strongly preferred to avoid short-term side effects (p=0.03). Latent class analysis showed significant differences of preferences across gender and insurance status. CONCLUSIONS In this national sample of mostly AML survivors, patients preferred treatments that maximized